Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $912.33M
- Beta
- 0.00
Volume 0.37M
Average 0.43M
ODTX Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Gross Profit history
Currency unavailable · from the income statement
No Gross Profit data reported for this period type.
Gross Profit vs competitors
How ODTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $281.59M USD | +34.6% | +19.0% | 99.9% | |
| LTM Mar 2026 | $270.54M USD | +582.2% | — | 116.4% | |
| LTM Sep 2026 | $45.25M USD | +200.0% | — | 50.0% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $6.53M USD | -66.1% | — | 88.2% |
| LTM Mar 2026 | $6.39M USD | +74.8% | -31.4% | 76.3% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €0 EUR | — | — | — |
| LTM Mar 2026 | -$33K USD | +50.0% | — | — | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | -$62.25M USD | — | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ODTX) | — | +62.4% | -6.2% | 88.2% | |
Competitors are the stored peer set for ODTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$18.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.